We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.
- Authors
Tan, An Sen; Yeong, Joe Poe Sheng; Lai, Chi Peng Timothy; Ong, Chong Hui Clara; Lee, Bernett; Lim, Jeffrey Chun Tatt; Thike, Aye Aye; Iqbal, Jabed; Dent, Rebecca Alexandra; Lim, Elaine Hsuen; Tan, Puay Hoon
- Abstract
The proliferation marker Ki-67 is frequently used to assess aggressiveness in the pathological evaluation of cancer, but its role remains uncertain in triple-negative breast cancer (TNBC). We aimed to quantify and localize Ki-67 expression in both epithelial and immune compartments in TNBC and investigate its association with clinicopathological parameters and survival outcomes. A total of 406 TNBC cases diagnosed between 2003 and 2015 at Singapore General Hospital were recruited. Using state-of-the-art, 7-colour multiplex immunofluorescence (mIF) tissue microarrays (TMAs) were stained to assess the abundance, density and spatial distribution of Ki-67-positive tumour cells and immune cells co-decorated with cytokeratin (CK) and leukocyte common antigen (CD45) respectively. Furthermore, MKI67 mRNA profiles were analysed using NanoString technology. In multivariate analysis adjusted for tumour size, histologic grade, age at diagnosis, and lymph node stage, a high Ki-67 labelling index (LI) > 0.3% was associated with improved disease-free survival (DFS; HR = 0.727; p = 0.027). High Ki-67-positive immune cell count per TMA was a favourable prognostic marker for both DFS (HR = 0.379; p = 0.00153) and overall survival (OS; HR = 0.473; p = 0.0482). The combination of high Ki-67 LI and high MKI67 expression was associated with improved DFS (HR = 0.239; p = 0.00639) and OS (HR = 0.213; p = 0.034). This study is among the first to highlight that Ki-67 is associated with favourable prognosis in an adjuvant setting in TNBC, and the mIF-based evaluation of Ki-67 expression on both tumour and immune cells represents a novel prognostic approach.
- Subjects
TRIPLE-negative breast cancer; PROGRESSION-free survival
- Publication
Virchows Archiv: European Journal of Pathology, 2019, Vol 475, Issue 6, p709
- ISSN
0945-6317
- Publication type
journal article
- DOI
10.1007/s00428-019-02635-4